Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 22, 2018

Early versus Later Treatment Start in Multiple Sclerosis - A Register Based Cohort Study (S8.007)

Thor A. Chalmer, Melinda Magyari, Lisbeth M. Baggesen, Mette Nørgaard, Nils Koch-Henriksen, Per Solberg Sorensen
First published April 9, 2018,
Thor A. Chalmer
1The Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Denmark København Ø Denmark
2Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark København Ø Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda Magyari
1The Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Denmark København Ø Denmark
2Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark København Ø Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisbeth M. Baggesen
3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark Aarhus Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mette Nørgaard
3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark Aarhus Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nils Koch-Henriksen
1The Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Denmark København Ø Denmark
3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark Aarhus Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Solberg Sorensen
2Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark København Ø Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Early versus Later Treatment Start in Multiple Sclerosis - A Register Based Cohort Study (S8.007)
Thor A. Chalmer, Melinda Magyari, Lisbeth M. Baggesen, Mette Nørgaard, Nils Koch-Henriksen, Per Solberg Sorensen
Neurology Apr 2018, 90 (15 Supplement) S8.007;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess long-term effects of disease-modifying therapy (DMT) initiated early in the disease course compared with later treatment start.

Background: The timing of DMT in patients with multiple sclerosis is assumed to be important for the time to reach confirmed disease worsening and the time to reach death. Observational studies based on nationwide registries are ideal to investigate treatment effectiveness in a real world population.

Design/Methods: We retrieved data on all Danish MS patients (n=3,795) treated with DMT from two nationwide population based MS registries. The cohort consisted of early treated patients, defined as treatment start within two years after the first MS symptom (n=2,316) and later treated patients, defined as treatment start between two and eight years from clinical onset (n=1,479). We compared time to progression to Expanded Disability Status Scale (EDSS) 6 and mortality between cohorts as hazard ratio (HR) using a Cox proportional hazards model with adjustment for inverse probability of treatment weights. Several sensitivity analyses were conducted.

Results: Median follow-up time was 10 years for both the EDSS 6 outcome (range 1–20) and mortality. Patients with later treatment start showed 28% increased hazard of reaching EDSS 6 compared with the early treated patients (HR 1.28; 95% CI 1.12–1.45). When stratified by sex the increased hazard among later treated women persisted (HR 1.39; 95% CI 1.19–1.63), while the HR decreased in men (1.09; 95% CI 0.89–1.35). Regarding mortality HR did not differ between early and later treatment start (HR 1.02; 95% CI 0.71–1.47).

Conclusions: Patients who started treatment with DMT late had shorter time to reaching EDSS 6 compared with patients who started early, but the delay did not influence mortality. Our results support the scheme of early treatment.

Study Supported by: This study was supported by The Danish Multiple Sclerosis Society; Foundation for Research in Neurology; Gangstefonden; Ejnar Jonassons called Johnsen and wife’s memorial fund.

Disclosure: Dr. Chalmer has received research support from received support for congress participation from Roche (ECTRIMS 2016) and Merck (ECTRIMS 2017). Dr. Magyari has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi, Teva, Roche, Novartis, Merck. Dr. Magyari has received research support from received support for congress participation from Biogen, Genzyme, Teva, Roche. Dr. Baggesen has nothing to disclose. Dr. Nørgaard has nothing to disclose. Dr. Koch-Henriksen has received research support from Travel expenses, accommodation, and congressional fees from Merck for participation to the 2017 ECTRIMS congress. Dr. Sorensen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck, Novartis, TEVA, GlaxoSmithKline, medDay Pharmaceuticals, Celgene, Genzyme, Novartis and Forward.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise